Human Immunodeficiency Virus Rebound in Blood and Seminal Plasma Following Discontinuation of Antiretroviral Therapy

被引:0
|
作者
Costiniuk, Cecilia T. [1 ]
Kovacs, Colin [2 ,3 ]
Routy, Jean-Pierre [4 ,5 ]
Singer, Joel [6 ]
Gurunathan, Sanjay [7 ]
Sekaly, Rafick-Pierre [8 ]
Angel, Jonathan B. [1 ,9 ]
机构
[1] Univ Ottawa, Div Infect Dis, Ottawa, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Maple Leaf Med Clin, Toronto, ON, Canada
[4] McGill Univ, Div Hematol, Ctr Hlth, Montreal, PQ, Canada
[5] McGill Univ, Serv Immunol, Ctr Hlth, Montreal, PQ, Canada
[6] CIHR Canadian HIV Trials Network, Vancouver, BC, Canada
[7] Sanofi Pasteur, Swiftwater, PA USA
[8] CHU Montreal, Ctr Rech, Montreal, PQ, Canada
[9] Ottawa Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada
基金
加拿大健康研究院;
关键词
SEXUAL TRANSMISSION; HIV-1; TRANSMISSION; SEMEN; INFECTION; INHIBITOR;
D O I
10.1089/aid.2011.0343
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although there is discordance between human immunodeficiency virus (HIV) blood plasma and seminal plasma viral loads (VL), little is known about the dynamics of VL rebound in these compartments upon discontinuation of highly active antiretroviral therapy (HAART). Therefore, we sought to examine the relationship between blood and semen VL rebound after discontinuation of HAART. Participants in this substudy were men enrolled from two centers of a multicenter, placebo-controlled randomized trial of HIV therapeutic vaccination using ALVAC with or without Remune. With at least 2 years of sustained virologic suppression and following a 20-week vaccination course, subjects underwent structured HAART interruption. Fourteen men provided semen samples. Seven to 12 weeks after HAART interruption, all 14 men had detectable blood VLs whereas 8 of 14 had detectable seminal VLs. There was a significant correlation between blood and seminal VLs (Spearman r=0.58, p=0.03) at the time of semen collection. An earlier time to detectable blood VL after HAART interruption was associated with higher seminal VL (Spearman r=-0.64, p=0.02). These findings support the compartmentalization of HIV and underscore the importance of understanding the genital tract as an HIV reservoir in the quest to minimize HIV transmission.
引用
收藏
页码:266 / 269
页数:4
相关论文
共 50 条
  • [31] Neurosurgery and human immunodeficiency virus in the era of combination antiretroviral therapy: a review
    Henderson, Duncan
    Sims-Williams, Hugh P.
    Wilhelm, Thomas
    Sims-Williams, Helen
    Bhagani, Sanjay
    Thorne, Lewis
    JOURNAL OF NEUROSURGERY, 2017, 126 (03) : 897 - 907
  • [32] Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients
    Turner, BJ
    JOURNAL OF INFECTIOUS DISEASES, 2002, 185 : S143 - S151
  • [33] Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update
    Zanetti, Hugo Ribeiro
    Roever, Leonardo
    Goncalves, Alexandre
    Resende, Elmiro Santos
    CURRENT ATHEROSCLEROSIS REPORTS, 2018, 20 (02)
  • [34] Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update
    Hugo Ribeiro Zanetti
    Leonardo Roever
    Alexandre Gonçalves
    Elmiro Santos Resende
    Current Atherosclerosis Reports, 2018, 20
  • [35] Lung Injury on Antiretroviral Therapy in Adults With Human Immunodeficiency Virus/Tuberculosis
    Ravimohan, Shruthi
    Auld, Sara C.
    Maenetje, Pholo
    Ratsela, Nelly
    Mlotshwa, Mandla
    Ncube, Itai
    Smith, Jonathan P.
    Vangu, Mboyo-di-Tamba
    Sebe, Modulakgotla
    Kossenkov, Andrew
    Weissman, Drew
    Wallis, Robert S.
    Churchyard, Gavin
    Kornfeld, Hardy
    Bisson, Gregory P.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (09) : 1845 - 1854
  • [36] ANTIRETROVIRAL THERAPY FOR INFECTION DUE TO HUMAN-IMMUNODEFICIENCY-VIRUS IN CHILDREN
    PIZZO, PA
    WILFERT, C
    CLINICAL INFECTIOUS DISEASES, 1994, 19 (01) : 177 - 196
  • [37] Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy
    Justesen, US
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 98 (01) : 20 - 31
  • [38] Antiretroviral Therapy for Treatment of Human Immunodeficiency Virus Type 1 Infection
    Oh, Myung Don
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2007, 50 (04): : 316 - 323
  • [39] The value and challenges of improving adherence to antiretroviral therapy for human immunodeficiency virus
    Johnson, Mallory O.
    Chesney, Margaret A.
    MEDICAL CARE, 2006, 44 (10) : 891 - 892
  • [40] Paronychia in patients receiving antiretroviral therapy for human immunodeficiency virus infection
    Sibel, S
    Macher, A
    Goosby, E
    JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION, 2000, 90 (02): : 98 - 100